Exclusive: Malaysia’s A-Bio invests $1.8m in pathology service provider Clinipath

Photo: Bloomberg

A-Bio, a strategic investment firm established by the Malaysian government, has invested RM7 million ($1.8 million) in Clinipath Malaysia, one of the country’s leading pathology service providers.

Clinipath, wholly owned by Malaysian Genomics Resource Centre, said the investment by A-Bio will help it improve its IT infrastructure, expand laboratories in key locations, and develop new clinical tests.

It also seeks to open up channels to scale up its operations in the local and regional markets. The company has a nationwide network of clinical laboratories serving doctors in hospitals, clinics, and research laboratories and is further venturing into modernisation of pathology.

“Malaysia’s clinical pathology industry offers tremendous growth potential. Improving pathology testing capabilities, including developing new technologies and tests using the latest genetics and genomics resources, will contribute directly to higher quality healthcare services in clinics and hospitals,” said Sasha Nordin, Chief Operating Officer, Malaysian Genomics.

Dr Norida Abdul Rahman, managing director of A-Bio, said the market for pathology services in Malaysia is huge and the impact of digitisation could be significant given that Malaysia is seeing a growth in its population and a high prevalence of chronic diseases.

“Bridging the gap with the digitalisation of healthcare services, A-Bio hopes to leapfrog Malaysia into the use of digital technology to help mitigate rising healthcare delivery costs,” he added.

Established in 2009 by the Malaysian government to foster high-growth enterprises in Malaysia, A-Bio invests in high value-added and high technologies industries, such as bio-industry and emerging technology domains.

The firm’s investment in Clinipath is in line with its mandate “to build and nurture the growth of Malaysia market leaders in niche focus areas of high-tech industry”, Abdul Rahman said.

According to figures provided by Malaysia’s Science, Technology and Innovation Ministry, the country has received investments worth RM6.7 billion ($1.71 billion) from 340 biotechnology firms to date. Of this amount, RM4.6 billion (69 per cent) was through foreign direct investment.

Malaysia’s biotechnology industry reportedly generated a total income of RM2.7 billion ($690.2 million) and created 31,000 job opportunities between 2011 and 2015.

Also Read:

Malaysia: A-BIO backs $5.1m strategic investment in Ain Medicare

Malaysia: PRG Healthcare to acquire Roopi Medical Centre for $4.6m

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.

Singapore Reporter/s

In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digitally savvy and ready to experiment with new forms of storytelling. Most importantly, we are looking for hard-hitting reporters who work well in a team. Collaboration and collegiality are a must.

Following vacancies can be applied for (only in Singapore).

Following vacancies can be applied for (only in Singapore).   

  • A reporter to track companies/startups that have raised private capital, and have the potential to become unicorns. SEA currently has over 40 companies with a valuation of over $100 million and under $1 billion.
  • A reporter who can get behind the scenes and reveal how funding rounds are put together, or why they’ve failed to materialise. She/he in this role will largely focus on long-format stories. 
  • A journalist to track special situations funds, distressed debt and private credit (from the PE angle) across Asia.